Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2016, Article ID 7802967, 5 pages
http://dx.doi.org/10.1155/2016/7802967
Review Article

HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide

Istituto di Ematologia, Universita’ Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Gemelli, Rome, Italy

Received 16 November 2015; Revised 11 February 2016; Accepted 14 March 2016

Academic Editor: Suparno Chakrabarti

Copyright © 2016 Andrea Bacigalupo and Simona Sica. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The use of high dose posttransplant cyclophosphamide (PT-CY) introduced by the Baltimore group approximately 10 years ago has been rapidly adopted worldwide and is becoming a standard for patients undergoing unmanipulated haploidentical (HAPLO) transplants. PT-CY has been used following nonmyeloablative as well as myeloablative conditioning regimens, for bone marrow or peripheral blood grafts, for patients with malignant and nonmalignant disorders. Retrospective comparisons of HAPLO grafts with conventional sibling and unrelated donor grafts have been published and suggest comparable outcome. The current questions to be answered include the use of PT-CY for sibling and unrelated donors transplant, possibly in the context of prospective randomized trial.